Evolution of some liver function markers after treatment in patients with schizophrenia and bipolar disorder

Introduction The prevalence of alterations of liver function tests in patients with schizophrenia and bipolar disorders is not well known. These alterations are often considered as side effects of medication Objectives Our study aimed to evaluate and compare liver function before and after treatment in patients with schizophrenia (SCZ), schizo-affective disorder (SCA) and bipolar disorder (BD). Methods This was a prospective study among patients with SCZ, SCA and BD according to DSM-5 criteria. Patients, from the “C” psychiatry department of Hedi Chaker University Hospital in Sfax, were assessed during both acute and remission phases in their illness. The acute phase (T0) assessment was made in drug-free patients from june 2016 to july 2018. As for the remission phase (T1), it was made between november 2019 and march 2020. Blood tests were performed in the Laboratory of Biochemistry at Habib Bourguiba University Hospital in Sfax. Clinical and biological parameters of patients were compared with those of healthy controls. Biological assessment consisted mainly in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Albumine. Results Thirty patients were included in our study. Their mean age was 35.83 ± 12.24 years and they were all males. They suffered from SCZ in 33.33% of cases, from SCA in 26.66% of cases and from BD in 40% of cases. Psychoactive substance use was common among 80% of patients. In the remission phase, 90% were polymedicated with use of antipsychotics in 83% of cases and mood stabilisers in 53% of cases. Table 1 shows the evolution of the studied liver function markers in our patients.Table 1: evolution of some liver function markers in patients Markers T0 T1 p AST (UI/L) Patients 33,22 ± 23,18 19,34 ± 4,97 <0,001 Controls 22,27±6,91 <0,05 e,b ALT (UI/L) Patients 19,59 ± 13,2 13,17 ± 11,39 0,003 Controls 20,63±11,08 <0,05 e,a,b Albumine (g/l) Patients 42,35±4,86 47,79±3,18 <0,001 Controls 46,19±3,95 >0,05 a: significant difference between patients with SCZ (T1) and controls; b: significant difference between patients with BD (T1) and controls; e: significant difference between patients (T1) and controls Conclusions Our results showed an improvement of liver function in patients with SCZ and BD after treatment. This suggests that liver function alterations are due to these diseases rather than the medication. Disclosure of Interest None Declared

Introduction: Autism spectrum disorder (ASD) is a disorder with social, communication and behavioral disturbances that start from early childhood.There are many difficulties in diagnosing people with ASD.The diagnostic criteria are in terms of behavior descriptions, and as methods of intervention the most used is the applied behavior analysis (ABA).Although, the treatment of autism is not based on drugs, there are a number of reports that sustains the vitamin supplementation.For example, the deficiency of vitamin D (VD) was often outlined in the serum of the ASD people.Nowadays, zebrafish (Danio rerio) plays an important role in the modeling era; being one of the main organisms used in animal studies.Objectives: In this study, we aimed to describe the influence of VD in autistic people, and the possibility of vitamin investigation through animal models studies.Methods: For analyzing this subject specific scientific databases were screened using certain keywords as: "autism spectrum disorder", "vitamin D", "treatment", "deficiency","animal models" and "zebrafish".Inclusion criteria were studies that (1) investigated a behavioral intervention, (2) used animal models for ASD modelling, (3) reported vitamin D results, and (4) were published within the last 20 years.Results: The majority of the studies supported the importance of an adequate level of VD in the body, mainly due to its implication during pregnancy and early brain development.The few existing data bring information about the positive impact of its administration in ASD children; in which a considerable improvement in typical symptoms was observed.For further knowledge about VD activity in ASD it was suggested the animal modelling, especially zebrafish organisms due to its numerous advantages (high similarity of its genome with the human one).Conclusions: VD deficiency during pregnancy and early brain development is a real risk factor besides genetic predisposition.Moreover, the use of animal models for investigating the effect of VD is required for a better understanding of the vitamin mechanism in ASD people.Acknowledgement: *R.M.-A.and B. M.-I.are supported by the Project POCU/993/6/13/153322 "Suport educațional și formativ pentru doctoranzi și tineri cercetători în pregătirea inserției în piața muncii" of the European Social Fund through the Human Capital Operational Program.

EPV0632
Evolution of some liver function markers after treatment in patients with schizophrenia and bipolar disorder S. Sellami1,2 , M. Maalej 2,3 *, M. Ayadi 2,4 , M. Naifar 2 , M. Maalej 3,5 and F. Ayadi 2 Introduction: The prevalence of alterations of liver function tests in patients with schizophrenia and bipolar disorders is not well known.These alterations are often considered as side effects of medication Objectives: Our study aimed to evaluate and compare liver function before and after treatment in patients with schizophrenia (SCZ), schizo-affective disorder (SCA) and bipolar disorder (BD).
Methods: This was a prospective study among patients with SCZ, SCA and BD according to DSM-5 criteria.Patients, from the "C" psychiatry department of Hedi Chaker University Hospital in Sfax, were assessed during both acute and remission phases in their illness.The acute phase (T0) assessment was made in drug-free patients from june 2016 to july 2018.As for the remission phase (T1), it was made between november 2019 and march 2020.Blood tests were performed in the Laboratory of Biochemistry at Habib Bourguiba University Hospital in Sfax.Clinical and biological parameters of patients were compared with those of healthy controls.Biological assessment consisted mainly in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Albumine.
Results: Thirty patients were included in our study.Their mean age was 35.83 AE 12.24 years and they were all males.They suffered from SCZ in 33.33% of cases, from SCA in 26.66% of cases and from BD in 40% of cases.Psychoactive substance use was common among 80% of patients.In the remission phase, 90% were polymedicated with use of antipsychotics in 83% of cases and mood stabilisers in 53% of cases.Table 1 shows the evolution of the studied liver function markers in our patients.
Conclusions: Our results showed an improvement of liver function in patients with SCZ and BD after treatment.This suggests that liver function alterations are due to these diseases rather than the medication.Introduction: We present the case of a 69-year-old patient who went to the emergency department due to an episode of aggressiveness and behavioral alteration, presenting irritability and nervousness, of about 2 days of evolution according to her family member.Given that the patient had previously presented chronic behavioral disorders and had previously been followed up in psychiatric consultations, psychiatry was notified after an initial evaluation by the emergency physician.Objectives: Somatic personal history: NAMC.HTA.Not DM, not DL.Former smoker of 20 cigarettes/day.Recurrent intracranial hemorrhage secondary to amyloid angiopathy and suspected amyloid vasculitis.Last admission to the neurology service in June 2022, also presenting symptomatic epileptic seizures and secondary behavioral alterations.Mastocytosis.Post-traumatic vertebral fracture.Non-anticoagulated paroxysmal atrial fibrillation.Surgical: Left ear surgery.appendectomy.Hysterectomy þ oophorectomy.Personal psychiatric history: In follow-up since May 2021 referred from neurology for emotional lability, episodes of anger and fear.Diagnosed with anxiety-depressive disorder secondary to a medical illness.Current psychiatric treatment: Oxcarbazepine 800mg 0-0-1, trazodone 100mg 0-0-1, aripiprazole 10mg 1-0-0.Methods: Current illness: The patient goes to the emergency room brought by her husband.During the interview she minimizes her aggressive behaviors or even does not remember them.She is disoriented in time, with very striking memory failures.Her husband comments verbal aggressiveness if he contradicts her in something, sometimes even presenting physical aggressiveness with her relatives.They report that in the last psychiatric consultation a little over 1 month ago, aripiprazole was withdrawn due to an increased risk of cardiovascular events.After the examination of the patient, she was referred back to the emergency department for a new assessment and to rule out the organicity of the current condition, given that the patient had cardiovascular risk factors, due to the suspicion of a new episode of intracranial hemorrhage.Results: sychopathological examination: Vigil, conscious, disoriented in time, partially in space.Collaborative, calm during the interview.Coherent, structured speech, with obvious memory failures.Labile, irritable mood.Verbal and physical heteroaggressiveness at home, not during the interview.No structured or planned autolytic ideation at this time.Appetite and sleep preserved.Conclusions: An urgent head CT was requested, with the result of a small intraparenchymal bleeding in the left frontal location, and she was admitted to the neurology department, with a diagnosis at discharge of: small left frontal haematoma, suspected amyloid vasculitis, and secondary behavioral alteration (vascular dementia).

EPV0634
Cyst of Septum Pellucidum in mental disorders: Schizophrenia and Mental Retardation: Two case reports M. Belak pedopsychiatric, psychiatric hospital Arrazi, salé, Morocco doi: 10.1192/j.eurpsy.2023.1953Introduction: A septum pellucidum cyst is defined as a fluid collection between the lateral ventricles whose walls have a lateral a : significant difference between patients with SCZ (T1) and controls; b: significant difference between patients with BD (T1) and controls; e: significant difference between patients (T1) and controls European Psychiatry S923 Monge 1 *, M. V. LOPEZ RODRIGO 1 , C. GARCIA MONTERO 2 , A. OSCA OLIVER 1 , V. R. FONS 1 and A. DUQUE DOMINGUEZ 2

Table 1 :
evolution of some liver function markers in patients